Defeat Duchenne Canada Launches New Clinical Trial Finder Tool
Defeat Duchenne Canada is proud to announce the launch of the first Clinical Trial Finder Tool for Duchenne and Becker muscular dystrophy in Canada.
Duchenne and Becker muscular dystrophy are progressive neuromuscular disorders with no cure. Affecting approximately 1 in every 5,000 boys in Canada, both Becker and Duchenne are caused by mutations within the dystrophin gene, one of the largest genes in the body responsible for strengthening muscles and protecting them from injury.
When the organization first began its quest for a cure twenty-six years ago, there was very little research and no clinical trials. Since then, numerous organizations, like Defeat Duchenne Canada, have transformed the landscape by investing in the most promising science focused on prevention, improved treatments, and a better quality of life for individuals living with Duchenne and Becker.
“We have developed an innovative Clinical Trial Finder Tool for those living with Duchenne and Becker muscular dystrophy. The tool helps gather comprehensive information on existing and pending clinical trials in Canada and beyond, allowing our community to easily personalize and navigate the latest information to help make informed choices about their participation,” shares Nicola Worsfold, Vice-President of Research, Advocacy and Education at Defeat Duchenne Canada.
“Being involved in a clinical trial is not a decision that can be made lightly,” she continues. “While it offers the possibility of hope, it also involves many sacrifices from the whole family. We want to empower our community with accurate, up-to-date information to facilitate informed decision making with their health care team.”
Watch the Defeat Duchenne Canada webinar launch of their Clinical Trial Finder Tool
Defeat Duchenne Canada has built a foundation of strong partnerships with leading scientists and industry partners to improve care for individuals living with Duchenne and Becker. When they heard the need from their community for more resources regarding clinical trials, the organization turned to Lumiio, a global digital health company specializing in real-world data collection services that drive health outcomes.
“We were thrilled to be able to work with Defeat Duchenne Canada in the development of a tool that helps close knowledge gaps around clinical trial opportunities,” said Josh Lounsberry, Chief Strategy Officer at Lumiio, “The needs of the Duchenne community align perfectly with Lumiio’s mission of accelerating health outcomes through data.”
Learn more about the Clinical Trial Finder Tool defeatduchenne.ca/clinicaltrials
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.